Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
Alimentary Pharmacology & Therapeutics · 2025-03 · 61 (5) · 835-851
DOI: 10.1111/apt.18458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 25.12.2024. Verfasst von Colin W Howden und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Tennessee College of Medicine, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Sulfonamides, Pyrroles, Proton Pump Inhibitors, Gastroesophageal Reflux. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Phathom Pharmaceuticals Inc..
Abstract (Originalsprache)
Background
Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents.
Aim
To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults.
Methods
We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided.
Results
Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug.
Conclusions
Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Tennessee College of Medicine, Memphis, Tennessee, USA.
- Division of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, New York, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
- Phathom Pharmaceuticals, Florham Park, New Jersey, USA.
ORCID-Profile: Philip Katz
Förderung
- Phathom Pharmaceuticals Inc.
Zitieren
APA
Howden, C. W., Katz, P., DeVault, K. R., Metz, D. C., Tamene, D., Smith, N., Hunt, B., Chang, Y. M., & Spechler, S. J. (2025). Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 61(5), 835-851. https://doi.org/10.1111/apt.18458
Vancouver
Howden CW, Katz P, DeVault KR, Metz DC, Tamene D, Smith N, et al. Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics. 2025;61(5):835-851. doi:10.1111/apt.18458
BibTeX
@article{Howden2025,
author = {Howden, Colin W and Katz, Philip and DeVault, Kenneth R and Metz, David C and Tamene, David and Smith, Neila and Hunt, Barbara and Chang, Yu-Ming and Spechler, Stuart J},
title = {Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {61},
number = {5},
pages = {835--851},
doi = {10.1111/apt.18458}
}
EUVIMED